New combo therapy aims to boost red blood cells in dialysis patients

NCT ID NCT07045155

Recruiting now Disease control Sponsor: Chinese PLA General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests a new drug called pegmolesatide, alone or combined with roxadustat, to treat anemia in 240 adults on dialysis for chronic kidney disease. Participants currently on another anemia drug (rHuEPO) will switch to one of three treatment plans for 24 weeks. The goal is to see which approach best raises and stabilizes hemoglobin levels.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pegmolesatide (a drug to stimulate red blood cell production), sometimes combined with roxadustat
What this could lead to: If successful, this could offer a more effective or convenient way to manage anemia in people on dialysis, potentially improving energy and quality of life.
What could go wrong: This is a phase 4 study with a modest size (240 participants) and open-label design, which can introduce bias. The combination therapy may also carry unknown side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE 5D are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anemia due to chronic disorder Bronchiolitis Obliterans Syndrome end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC KIDNEY DISEASE 5D DIALYSIS; COMPLICATIONS RENAL ANAEMIA RENAL ANEMIA OF CHRONIC KIDNEY DISEASE RENAL ANEMIA, CHRONIC

Contacts and locations

Locations

Chinese PLA General Hospital
RECRUITING

Beijing, Beijing Municipality, 100000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.